Vera Therapeutics

Happy Valley, a BBC series, starred Sarah Lancashire as Sgt Catherine Cawood, who dealt with her daughter's suicide and a kidnapping case involving her ex, Tommy Lee Royce. The show became the UK's second most-watched TV series in 2022. Post-series, Lancashire played Julia Child and will star in Black Doves. James Norton, who played Tommy, is rumored to be the next James Bond. Siobhan Finneran, who played Clare, starred in Downton Abbey and Cold Feet. Rhys Connah, who played Ryan, has no upcoming projects. Charlie Murphy, who played Ann Gallagher, starred in Peaky Blinders and Halo. Derek Riddell, who played Richard Cawood, starred in The Missing and Industry. Con O'Neill, who played Neil Ackroyd, starred in Chernobyl and Our Flag Means Death. George Costigan, who played Nevison Gallagher, starred in Line of Duty and Gentleman Jack. Amit Shah, who played Faisal Bhatti, starred in Black Mirror and Doctor Who. Rick Warden, who played Mike Taylor, starred in Band of Brothers and Sherlock.

Vera Therapeutics' Form 10-Q report reveals a net loss of $(46.6) million, up 132% YoY, with total operating expenses at $49.8 million. The company is advancing atacicept in Phase 3 ORIGIN 3 trial for IgAN, with topline results expected Q2 2025, and plans to initiate Phase 2 PIONEER trial in 2025 for non-IgAN autoimmune kidney diseases. Vera Therapeutics aims to expand atacicept's therapeutic indications and is preparing for regulatory submissions for IgAN in 2025. The company faces financial, regulatory, and competitive risks, necessitating ongoing capital management and strategic initiatives.

Vera Therapeutics (VERA) is a biotech company developing atacicept for autoimmune diseases like IgA nephropathy (IgAN) and lupus nephritis, showing promising results in Phase 2b ORIGIN trial. The company also advances MAU868 for BK virus infections in kidney transplant patients. Vera reported a net loss of $28.4 million for Q1 2024 but has sufficient cash reserves. The FDA granted Breakthrough Therapy Designation to atacicept for IgAN, expediting its development.